Tumor-specific IL-9–producing CD8+Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers

• DOI: 10.1073/pnas.1317431111
• Publication Date: 2014-01-28T05:29:52Z
• Authors: Yong Lu; Bangxing Hong; Haiyan Li; Yuhuan Zheng; Mingjun Zhang; Siqing Wang; Jianfei Qian; Qing Yi
• Keywords: Adoptive Cell Transfer; Cancer Immunotherapy

Significance Our laboratory has identified a critical role of IL-9 in promoting endogenous tumor-specific cytotoxic T lymphocyte response. In this study, we found that differentiation CD8 + cells under helper 9-polarizing conditions induces the development an IL-9–producing less cytolytic IL-9–skewed (Tc9) cell subset. Noticeably, adoptive transfer tumor-reactive Tc9 elicited greater antitumor responses against large established tumors than classic type-I are used clinical protocols. Importantly, have substantially enhanced persistence potential and possess capacity to acquire/maintain effector function after transfer. results also revealed Tc9-mediated therapeutic effect critically depended on production vivo. The ability confer sustained might open avenue for advances cancer immunotherapy.